Filtering





DOP41: Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based studyECCO'21 Virtual
Year: 2021
Authors: Quaresma, A.B.(1);Damiao, A.O.M.C.(2);Coy, C.S.R.(3);Magro, D.O.(3);Valverde, D.A.(4);Panaccione, R.(5);Coward, S.B.(6);Ng, S.C.(7);Kaplan, G.G.(6);Kotze, P.G.(8)
(1)Universidade do Oeste Catarinense UNOESC, Colorectal Surgery, Joaçaba, Brazil;(2)University of Sao Paulo, Gastroenterology, Sao Paulo, Brazil;(3)University of Campinas UNICAMP, Colorectal Surgery Unit, Campinas, Brazil;(4)Techtrials Healthcare, Data Science, Vinhedo, Brazil;(5)University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;(6)University of Calgary, Department of Medicine and Community Health Sciences, Calgary, Canada;(7)Chinese University of Hong Kong, Department of Gastroenterology, Hong Kong, Hong Kong- China;(8)Catholic University or Paraná, IBD outpatient Clinics- Colorectal Surgery Unit, Curitiba, Brazil
DOP42: Disease course and clinical outcomes in Taiwan Crohn’s Disease patients with perianal fistula: A nationwide-based studyECCO'21 Virtual
Year: 2021
Authors: Weng, M.T.(1);Lin, K.L.(2);Chan, K.A.(3);Wei, S.C.(4)
(1)National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan- Province Of China;(2)National Taiwan University, Health Data Research Center, Taipei, Taiwan- Province Of China;(3)National Taiwan University, Health Data Research Center, Taipeit, Taiwan- Province Of China;(4)National Taiwan University Hospital, Departments of Internal Medicine, Taipei, Taiwan- Province Of China
DOP43: Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathiesECCO'21 Virtual
Year: 2021
Authors: Attauabi, M.(1,2,3);Damsgaard Wewer, M.(1,3);Bendtsen, F.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3)
(1)Copenhagen University Hospital, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark
DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRNECCO'21 Virtual
Year: 2021
Authors: Magen Rimon, R.(1);Atia, O.(2);Friss, C.(2);Ledderman, N.(3);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband, Y.(5);Gabay, C.(5);Shaoul, R.(1);Odes, S.(6);Matz, E.(7);Dotan, I.(8);Turner, D.(2)
(1)Rambam Medical Center, Pediatric Gastroenterology & Nutrition institute, Haifa, Israel;(2)Shaare Zedek Medical Center, Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(3)Meuhedet Health Services, Meuhedet Health Services, Tel Aviv, Israel;(4)Maccabi Health Services, Maccabi Health Services, Tel Aviv, Israel;(5)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(6)Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel;(7)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(8)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRNECCO'21 Virtual
Year: 2021
Authors: Atia, O.(1); Yogev, D.(1);Chagit, F.(1);Gili, F.(1); Orlanski-Meyer, E.(1);Magen Rimon, R.(2);Natan, L.(3);Shira, G.(4); Kariv, R.(4);Yisca, L.W.(5); Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Gorelik, Y.(8); Chowers, Y.(8);Iris, D.(9);Turner, D.(1)
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel., Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Pediatric Gastroenterology & Nutrition institute- Ruth Rappaport Children's Hospital- Rambam Medical Center, Faculty of Medicine- Technion, Haifa, Israel;(3)Meuhedet Health Services, Meuhedet Health Services, Tel-Aviv, Israel;(4)Maccabi Health Services, The Sackler Faculty of Medicine- Tel Aviv University- Israel., Tel-Aviv, Israel;(5)Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel;(6)Department of Statistics and Operations Research, Tel Aviv University- Israel, Tel Aviv, Israel;(7)Leumit Health Services, Leumit Health Services, Tel-Aviv, Israel;(8)Technion Israel Institute of Technology- Department of Gastroenterology, Rambam Healthcare Campus- Bruce Rappaport School of Medicine, Haifa, Israel;(9)Division of Gastroenterology- Rabin Medical Center, The Sackler Faculty of Medicine- Tel Aviv University- Israel, Petah Tikva, Israel
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohortECCO'21 Virtual
Year: 2021
Authors: Atia, O.(1); Friss, C.(1);Mendelovici, A.(1); Shteyer, E.(1); Yogev, D.(1);Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4); Gabay, H.(4); Nevo, D.(5); Matz, E.(6); Dotan, I.(7);Turner, D.(1)
(1)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel., Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Jerusalem, Israel;(2)Meuhedet Health Services, Meuhedet Health Services, Tel-Aviv, Israel;(3)Maccabi Health Services-, he Sackler Faculty of Medicine- Tel Aviv University- Israel., Tel Aviv, Israel;(4)Clalit Health Services, Clalit Research Institute, Tel-Aviv, Israel;(5)Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel;(6)Leumit Health Services-, . Leumit Health Services, Tel-Aviv, Israel;(7)Division of Gastroenterology- Rabin Medical Center, the Sackler Faculty of Medicine- Tel Aviv University- Israel., Petah Tikva, Israel
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD StudyECCO'21 Virtual
Year: 2021
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);Di Giuseppe, R.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atreya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann , P.(1);Schreiber, S.(13)
(1)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis, Minden, Germany;(2)Kompetenznetz Darmerkrankungen e.V., Abteilung Studien, Kiel, Germany;(3)Kompetenznetz Darmerkrankungen e.V., Epidemiology and Biometry, Kiel, Germany;(4)Gastroenterology Practice, Innere Medizin- Gastroenterologie- Ärztliches Qualitätsmanagement, Saarbrücken, Germany;(5)Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselerkrankungen, Innere Medizin- Gastroenterologie- Hepatologie- Proktologie, Münster, Germany;(6)Gastroenterology Practice, Medizinisches Versorgungszentrum, Iserlohn, Germany;(7)Gastroenterologische Gemeinschaftspraxis, Innere Medizin- Gastroenterologie- Hepatologie- Proktologie, Münster, Germany;(8)Gastroenterologische Gemeinschaftspraxis Herne, Gastroenterologische, Herne, Germany;(9)University Hospital Heidelberg, Department of Gastroenterology and Hepatology, Heidelberg, Germany;(10)Universitätsklinikum Erlangen, Innere Medizin, Erlangen, Germany;(11)Gastroenterological practice, Gastroenterology, Kassel, Germany;(12)Goethe-Universität Frankfurt am Main, Innere Medizin- Gastroenterologie- Ernährungsmedizin, Frankfurt am Main, Germany;(13)Universitätsklinikum Schleswig-Holstein UKSH, Klinik für Innere Medizin I, Kiel, Germany
DOP48: Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn’s Disease (CD) in the U.S.ECCO'21 Virtual
Year: 2021
Authors: Huang, Z.(1);Ba, Y.(1);Kamble, P.(1);Wang, S.(1)
(1)Takeda, Gastroenterology- Global Outcomes, Cambridge, United States
DOP49: Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-GroupECCO'21 Virtual
Year: 2021
Authors: Pugliese, D.(1);Privitera, G.(2);Armuzzi, A.(3)
(1)Fondazione Policlinico Universitario Agostino Gemelli IRCCS, CEMAD-IBD UNIT- Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Rome, Italy;(2)Università Cattolica del Sacro Cuore, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Rome, Italy;(3)Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica, CEMAD - IBD Unit- Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Rome, Italy; LIVE STUDY GROUP
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Ledder, O.(1);Lujan, R.(1);Orlanski-Meyer, E.(1);Friss, C.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Focht, G.(1);Yanai, H.(6);Ollech, Y.(6);Dotan, I.(6);Turner, D.(1)
(1)Shaare Zedek Medical Center, Department of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Clalit Health Services, Clalit Research Institute, Tel Aviv, Israel;(3)Maccabi Healthcare Services, Maccabi Healthcare Services, Tel Aviv, Israel;(4)Meuhedet Health Services, Meuhedet Health ServicesTel, Tel Aviv, Israel;(5)Leumit Health Services, Leumit Health Services, Tel Aviv, Israel;(6)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalationECCO'21 Virtual
Year: 2021
Authors: Thomas, P.(1);Smits, L.(1);Te Groen, M.(1);West, R.(2);Russel, M.(3);Jansen, J.(4);Römkens, T.(5);Hoentjen, F.(1)
(1)Radboudumc, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Franciscus Gasthuis & Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(3)Medisch Spectrum Twente, Gastroenterology and Hepatology, Enschede, The Netherlands;(4)Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Jeroen Bosch Ziekenhuis, Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands
DOP52: Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)ECCO'21 Virtual
Year: 2021
Authors: Chaparro, M.(1);García Donday, M.(1);Calviño Suarez, C.(2);Rubio, S.(3);Figueira, M.(4);Pérez Martínez, I.(5);Leo Carnerero, E.(6);Rodríguez Lago, I.(7);Ruiz Cerulla, A.(8);Aguas, M.(9);López Serrano, P.(10);Ramírez de la Piscina Urraca, P.(11);Rivero, M.(12);Suarez Ferrer, C.(13);Alfambra Cabrejas, E.(14);Armesto, R.(15);Diz-Lois Palomares, M.T.(16);Guerra, I.(17); Vázquez Morón, J.M.(18); Casanova, M.J.(1);Hervías Cruz, D.(19); Huguet, J.M.(20); de Jorge Turrión, M.Á.(21); Marín Pedrosa, S.(22);Molina Arriero, G.(23);Ramos, L.(24);Zúñiga de Mora-Figueroa, B.(25);Camargo Camero, R.(26);Fernández-Clotet, A.(27);Gutiérrez Casbas, A.(28);Martínez Montiel, P.(29);Rodríguez Insa, R.(30);Sendra Rumbeu, P.(31);Tardillo Marín, C.(32);Vicente Lidón, R.(33);Arias García, L.(34);Bujanda, L.(35);Lucendo, A.J.(36);Manceñido Marcos, N.(37);Gisbert, J.P.(1)
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(3)Complejo Hospitalario Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(4)Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación de Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS UVIGO, Gastroenterology Unit, Vigo, Spain;(5)Hospital Universitario Central de Asturias e Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(6)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(7)Hospital de Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(8)Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain;(9)Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain;(10)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(11)Hospital Universitario de Álava, Gastroenterology Unit, Álava, Spain;(12)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(13)Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain;(14)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(15)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(16)Complexo Hospitalario Universitario de A Coruña, Gastroenterology Unit, A Coruña, Spain;(17)Hospital Universitario de Fuenlabrada e Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(18)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(19)Hospital General Universitario de Cuidad Real, Gastroenterology Unit, Cuidad Real, Spain;(20)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(21)Hospital Universitario de Cabueñes, Gastroenterology Unit, Gijón, Spain;(22)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(23)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(24)Hospital Universitario de Canarias, Gastroenterology Unit, Tenerife, Spain;(25)Hospital Clínico Universitario San Cecilio, Gastroenterology Unit, Granada, Spain;(26)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(27)Hospital Universitario Clìnic i Provincial and CIBEREHD, Gastroenterology Unit, Barcelona, Spain;(28)Hospital General Universitario de Alicante- CIBERehd and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Unit, Alicante, Spain;(29)Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain;(30)Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain;(31)Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(32)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Unit, Tenerife, Spain;(33)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(34)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(35)Instituto Biodonostia- Universidad del País Vasco UPV/EHU y CIBEREHD, Gastroenterology Unit, Guipúzcoa, Spain;(36)Hospital General de Tomelloso. Instituto de Investigación Sanitaria Princesa IIS-IP. CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain;(37)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain; on behalf of DUMBO study group
DOP53: Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s DiseaseECCO'21 Virtual
Year: 2021
Authors: Dubinsky, M.C.(1);Mahadevan, U.(2);Charles, L.(3);Afsari, S.(3);Henry, A.(3);Comi, G.(4);Selmaj, K.(5);van der Woude, C.J.(6)
(1)Icahn School of Medicine, Pediatrics- Gastroenterology, Mount Sinai, United States;(2)University of California San Francisco, Gastroenterology, San Francisco, United States;(3)Bristol Myers Squibb, Global Drug Safety & Risk Mgmt, Princeton, United States;(4)San Raffaele Scientific Institute- Vita-Salute San Raffaele University, Department of Neurology, Milan, Italy;(5)Center for Neurology- Łódź- Poland and Collegium Medicum- University of Warmia and Mazury, Department of Neurology, Olsztyn, Poland;(6)Erasmus MC, Gastroenterology, Rotterdam, Netherlands Antilles
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?ECCO'21 Virtual
Year: 2021
Authors: Rezazadeh Ardabili, A.(1,2);Jeuring, S.F.G.(1);Mujagic, Z.(1,2);Romberg-Camps, M.J.L.(3);van Bodegraven, A.A.(3);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2)
(1)Department of Internal Medicine- Division of Gastroenterology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(2)School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands;(3)Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands
DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s DiseaseECCO'21 Virtual
Year: 2021
Authors: Rezazadeh Ardabili, A.(1,2);Goudkade, D.(3);Wintjens, D.S.J.(1,2);Romberg-Camps, M.J.L.(4);Winkens, B.(5);Pierik, M.J.(1,2);Grabsch, H.I.(6,7);Jonkers, D.M.A.E.(1,2)
(1)Department of Internal Medicine- Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(2)School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands;(3)Department of Pathology, Zuyderland Medical Centre, Geleen, The Netherlands;(4)Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands;(5)Department of Methodology and Statistics- Care and Public Health Research Institute CAPHRI, Maastricht University, Maastricht, The Netherlands;(6)Department of Pathology- GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands;(7)Division of Pathology & Data Analytics- Lees Institute of Medical Research at St. James's, Univeristy of Leeds, Leeds, United Kingdom
DOP56: has been withdrawnECCO'21 Virtual
Year: 2021
DOP57: Predictive modelling to examine long term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s DiseaseECCO'21 Virtual
Year: 2021
Authors: Maruszczak, M.(1);Genenz, K.(2);Turkstra, E.(3);Fenu, E.(2);Hantsbarger, G.(4);Gilaberte, I.(5);Karki, C.(6);Panes, J.(7)
(1)Parexel International, Data Analytics and Machine Learning, Uxbridge, United Kingdom;(2)Takeda Pharmaceuticals, Takeda Pharmaceuticals, Zurich, Switzerland;(3)Parexel International, Parexel Access Consulting, Uxbridge, United Kingdom;(4)Takeda Pharmaceuticals USA- Inc, Statistical and Quantitative Sciences, Cambridge, United States;(5)Takeda Pharmaceuticals USA- Inc, Clinical Sciences, Cambridge, United States;(6)Takeda Pharmaceuticals USA- Inc, Global Evidence and Outcomes, Cambridge, United States;(7)Hospital Clínic de Barcelona- IDIBAPS, Gastroenterology Department, Barcelona, Spain
DOP58: Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in Ulcerative Colitis: A post-hoc analysis of individual level data from golimumab clinical trialsECCO'21 Virtual
Year: 2021
Authors: Greywoode, R.(1);Petralia, F.(2);Ullman, T.(1);Colombel, J.F.(3);Ungaro, R.(3)
(1)Montefiore Medical Center, Division of Gastroenterology, Bronx, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, New York, United States;(3)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States
DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscoreECCO'21 Virtual
Year: 2021
Authors: Lee, S.D.(1);Allegretti, J.R.(2);Steinwurz, F.(3);Connelly, S.B.(4);Lawendy, N.(4);Paulissen, J.(5);Gecse, K.B.(6)
(1)Digestive Health Center, University of Washington Medical Center, Seattle- Washington, United States;(2)Division of Gastroenterology- Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston- Massachusetts, United States;(3)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(4)Pfizer Inc, Collegeville, Pennsylvania, United States;(5)Pfizer Inc, New York, New York, United States;(6)Amsterdam UMC, Amsterdam, The Netherlands
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study dataECCO'21 Virtual
Year: 2021
Authors: Mantzaris, G.(1);Yarur, A.(2);Wang, S.(3);Adsul, S.(4);Kamble, P.(4);Luo, M.(3);Guerin, A.(5);Billmyer, E.(5);Nguyen, H.(5);Bressler, B.(6)
(1)Evangelismos Hospital, Department of Gastroenterology, Athens, Greece;(2)Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, United States;(3)Takeda Pharmaceuticals, Takeda, Cambridge, United States;(4)Takeda Pharmaceuticals-, Takeda, Cambridge, United States;(5)Analysis Group, Analysis Group, Boston, United States;(6)St. Paul’s Hospital, Division of Gastroenterology- Department of Medicine, Vancouver, Canada